CORRECTING and REPLACING Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy
Please replace the release with the following corrected version due to multiple revisions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/
New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics)
The corrected release reads:
EBOLA SUCCESSFULLY NEUTRALIZED BY LATEST GENERATION POLYCLONAL IMMUNOTHERAPY
Promising new platform can rapidly respond to emerging infectious diseases
Sioux Falls, SD, August 15, 2018 – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted at the Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Naval Medical Research Center (NMRC) and others.
According to the World Health Organization, Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans with an average fatality rate around 50%. Case fatality rates have varied from 25% to 90% in past outbreaks, and there is currently no licensed treatment proven to neutralize the virus.
During recent outbreaks of EVD in West Africa, passive immunotherapy with convalescent plasma containing polyclonal antibodies from recovered patients was used as an effective treatment. However, the amount and availability of these medicines are limited by the number of survivors.
SAB-139 was produced from SAB’s proprietary DiversitAb™ platform utilizing transgenic cattle (Tc Bovine™) to produce large amounts of natural human, rather than bovine, antibodies in response to an antigen—in this case EVD.
“This study demonstrates that a human polyclonal antibody-based product can be used to prevent EVD in the most advanced animal model available. This is impressive when one considers that SAB-139 did not require the use of plasma or cells from human EVD survivors,” said Jay Hooper, M.D., chief of the molecular virology branch of USAMRIID. “The ability to rapidly produce a human polyclonal antibody product without the need for material from infected animals or humans could be particularly useful when combating novel emerging infectious diseases.”
In the study, all animals treated with SAB-139 at one-day or three-days post-infection survived versus none of the control animals. In addition, the animals treated with SAB-139 exhibited no symptoms of EVD.
“Polyclonal antibodies are a powerful tool against emerging infectious diseases,” said Eddie J. Sullivan, PhD, SAB Biotherapeutics president and CEO. “They are our body’s natural defense to combat pathogens. With our platform, we can rapidly produce large amounts of targeted human antibodies without using humans—the limiting factor in current convalescent therapies in responding to a widespread outbreak.”
To produce the immunotherapy, Tc Bovine were vaccinated with the EVD antigen. Within a brief period of time, they produced significant amounts of fully human antibodies to combat the virus. Plasma was then collected, in the same way it’s collected from human donors, and purified to isolate the antibodies that become the treatment.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical stage biopharmaceutical company leading the science and manufacturing of human antibody therapeutics. Utilizing some of the most advanced polyclonal antibody science, SAB is delivering the world’s first large-scale platform to create fully human immunoglobulins. This natural production platform holds the potential for treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.
For SAB Biotherapeutics, Inc.
Melissa Ullerich, +1 605-695-8350
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
FRISS: Insurance Carriers Prioritize Fraud Detection and Prevention19.11.2018 13:00 | Pressemelding
Insurance fraud is a global problem. In the U.S. alone, insurance carriers lost over $34 billion in 2017 on fraudulent insurance claims. It’s a global problem with a growing number of technological solutions. Big data analysis and large-scale collaboration are key to fighting insurance fraud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181119005015/en/ Insurance Fraud Report by FRISS (Graphic: Business Wire) The insurance industry is increasingly focused on preventing fraud through innovative systems, relying on the assistance of specialized vendors to help accomplish the task. The burden of detecting and reducing fraud, therefore, no longer lies with the individual insurer. The 2018 FRISS Insurance Fraud Survey reached over 150 industry professionals and shows a clear picture of the current awareness and challenges of fraud detection and mitigation. Key survey findings show: Increased focus on data quality The quality of
BOC Group´s ADOIT Receives the Highest Score in “Rearchitecting the Enterprise for Transformation” Use Case in Gartner’s 2018 Critical Capabilities for Enterprise Architecture Tools19.11.2018 12:04 | Pressemelding
BOC Group, the leading global provider of Enterprise Management Solutions, is pleased to share its recognition in Gartner’s latest Critical Capabilities Report for Enterprise Architecture Tools*. ADOIT scores within the two highest across all three use cases, while scoring the highest out of eleven tools in “Rearchitecting the Enterprise for Transformation” use case. Christoph Moser, ADOIT product manager comments: "It is satisfying to be recognized by Gartner for our capabilities, which we are certain is due to our unique value proposition and holistic offering. We believe that our scores in this year's Gartner Critical Capabilities for Enterprise Architecture Tools report demonstrate our strength, innovation and continued investment in the agility, flexibility and versatility of our EA portfolio”. The Business Transformation Suite ADOIT supports customers worldwide in the digital transformation of their enterprise, facilitates alignment of their business and IT, and helps generate va
Chubu Centrair International Airport Has Been Ranked 5-Star Airport for Second Time19.11.2018 11:19 | Pressemelding
Chubu Centrair International Airport has been ranked for the second consecutive year as a 5-star Airport*1, the world highest airport rank, in the Regional Airport*2 category. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181119005317/en/ In order to reply to the diversifying needs of the increasing international travellers, Chubu Centrair International Airport is aiming to become an easier to use and a more comfortable airport. In SKYTRAX’s*3 survey, which includes over 500 airport evaluation categories, Chubu Centrair International Airport has ranked specially high in “Airport staff service” and ”Airport cleanness” among other airports. In addition, Chubu Centrair International Airport has been also awarded in SKYTRAX’s “World Airport Awards”, an international airport rating based on client service, as “The World’s Best Regional Airport” (for 4th consecutive year since 2015) and ”Best Regional Airport-Asia” (for 8th conse
Blommer Chocolate to Be Acquired by Fuji Oil Holding19.11.2018 09:03 | Pressemelding
The Blommer Chocolate Company, the largest ingredient chocolate manufacturer in North America and third largest in the world, announced that it has entered into an agreement to be acquired by Fuji Oil Holding, Inc., a global leader in oil and fat ingredients serving the food industry. The sale includes all Blommer business entities, including its four manufacturing operations in North America and one in Shanghai. Blommer is a private, family-owned company; Fuji Oil is publicly traded on the Tokyo Stock Exchange. “For nearly 80 years, our family business has grown to become a major ingredients supplier to most of the iconic brands across a wide variety of food categories,” said Peter Blommer, CEO and third-generation family member. “This is a landmark event in the proud history of Blommer Chocolate Company and begins an exciting new chapter as we look forward to joining a highly respected global leader in Fuji Oil. Our companies share common values and a deep commitment to product quali
GSMA Announces New Speakers for Mobile 360 Series – MENA19.11.2018 09:00 | Pressemelding
The GSMA today announced a number of additional high-profile speakers for its Mobile 360 Series – MENA (Middle East and North Africa) conference taking place on the 26-27 November 2018 in Dubai. The mobile industry-focused event, which is now in its sixth year, will cover the key industry issues facing the region, with a particular emphasis on transformative technologies including artificial intelligence (AI), blockchain and 5G. “Mobile is having a transformative impact across this diverse region with mobile operators in the GCC states laying the foundations for leadership in 5G and planning ahead to commercial launches, while the region’s emerging markets are seeing rising smartphone adoption,” said John Giusti, Chief Regulatory Officer, GSMA. “We have a incredible line-up of expert speakers this year, ready to outline the key issues and challenges facing the region – we’re looking forward to a thought-provoking and exciting showcase.” New speakers added to the agenda include: Hakam K
Telefónica Deutschland Selects SIAE MICROELETTRONICA for Turn-Key DCN Migration Services in Germany19.11.2018 08:00 | Pressemelding
Telefónica Deutschland , a leading integrated telecommunications provider in Germany awards SIAE MICROELETTRONICA, a long-term strategic partner for wireless transmission solutions, a turn-key contract for DCN (Data Communication Networks) migration services across its backhaul network. Following the successful acquisition of E-Plus, Telefónica Deutschland new backhaul network counts over 30.000 microwave radio links from three different vendors, including SIAE MICROELETTRONICA. In preparation for a potential 5G launch in the future, Telefónica is taking steps to simplify operations and maximize performances and coherence across its network. With these activities Telefónica plans to update its DCN by implementing a new common-DCN architectural model. The migration services entrusted to SIAE MICROELETTRONICA include project- management, IP network design, new-model implementation and operation service delivery. The cluster-by-cluster migration process consists of a mix of remote configu